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Background: Acute respiratory distress syndrome (ARDS) is a severe 
critical condition with a high mortality that is currently in focus 
given that it is associated with mortality caused by coronavirus 
disease 2019 (COVID-19). Neutrophils play a key role in the lung injury 
characteristic of non-COVID-19 ARDS and there is also accumulating 
evidence of neutrophil mediated lung injury in patients who succumb 
to infection with severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). 
Methods: We undertook a functional proteomic and metabolomic 
survey of circulating neutrophil populations, comparing patients with 
COVID-19 ARDS and non-COVID-19 ARDS to understand the molecular 
basis of neutrophil dysregulation. 
Results: Expansion of the circulating neutrophil compartment and the 
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presence of activated low and normal density mature and immature 
neutrophil populations occurs in ARDS, irrespective of cause. Release 
of neutrophil granule proteins, neutrophil activation of the clotting 
cascade and upregulation of the Mac-1 platelet binding complex with 
formation of neutrophil platelet aggregates is exaggerated in COVID-
19 ARDS. Importantly, activation of components of the neutrophil type 
I interferon responses is seen in ARDS following infection with SARS-
CoV-2, with associated rewiring of neutrophil metabolism, and the 
upregulation of antigen processing and presentation. Whilst 
dexamethasone treatment constricts the immature low density 
neutrophil population, it does not impact upon prothrombotic 
hyperinflammatory neutrophil signatures. 
Conclusions: Given the crucial role of neutrophils in ARDS and the 
evidence of a disordered myeloid response observed in COVID-19 
patients, this work maps the molecular basis for neutrophil 
reprogramming in the distinct clinical entities of COVID-19 and non-
COVID-19 ARDS.
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Introduction
Coronavirus disease 2019 (COVID-19) is an acute respiratory 
condition caused by novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection. In the most severe cases 
(termed “Critical COVID-19”), infection with SARS-CoV-2 can 
lead to the development of acute respiratory distress syndrome 
(ARDS)1. ARDS is a clinical syndrome defined by the presence 
of bilateral pulmonary infiltrates on chest radiograph and arte-
rial hypoxaemia that develops acutely in response to a known 
or suspected insult. ARDS is known to be the consequence of 
disordered inflammation2, and is characterised by a protein-rich 
oedema in the alveoli and lung interstitium, driven by epithelial 
and vascular injury2,3 and increased vascular permeability4,5. Lim-
ited data exists regarding the mechanisms causing hypoxaemia 
and lung inflammation following infection with SARS-CoV-2, 
although post-mortem case reports provide evidence of diffuse 
alveolar damage, with the presence of proteinaceous exudates in the 
alveolar spaces, intra-alveolar fibrin and alveolar wall expansion6. 
In previously described ARDS cohorts in which SARS-CoV-2 
was not an aetiological factor, alveolar damage is associated 
with worsening hypoxia and increased mortality7. In this context, 
hypoxia is a key driver of dysfunctional inflammation in the lung, 
augmenting neutrophil persistence and survival8,9 and promoting 
the release of pro-inflammatory mediators that cause ongoing tissue 
injury2,3. Non-dyspnoeic hypoxia is widely described in patients 
with severe COVID-1910, where it is associated with altered 
circulating leukocyte profiles with an increase in neutrophil to 
lymphocyte ratios and the presence of lymphopaenia11,12. More 
recently, post-mortem studies have revealed that the diffuse 
alveolar damage does not directly associate with the detection of 
virus, supporting the concept of aberrant host immune responses 
as drivers of tissue injury and pulmonary disease progression13. 
A disordered myeloid response is further evidenced by 
analysis of gene clusters and surface protein expression of 
whole blood and peripheral blood mononuclear cell (PBMC) 
layers of patients with mild and severe COVID-1914. However, 
the functional relevance of these transcriptional signatures 
remains to be explored given the limited reliance of neutrophils 
on transcription to regulate protein expression15. It also remains 
to be addressed whether the observed changes in neutrophil 
sub-populations are specific to COVID-19 ARDS or a reflection 
of the aberrant neutrophil inflammatory responses more broadly 
associated with the pathogenesis of ARDS. It is also unclear 
as to how these may be impacted by anti-inflammatory strate-
gies including dexamethasone, which has been shown to lower 
28-day mortality for patients receiving invasive mechanical 
ventilation or oxygen alone16.
One of the distinct features of COVID-19 that has emerged is 
the clinical evidence of a pro-thrombotic state, neutrophil reten-
tion within the lung microvasculature and the colocalisation of 
neutrophils with platelets in fibrin rich clots17. Together with 
evidence of the formation of neutrophil extracellular traps 
(NETs)18,19, this raises the important question as to whether neu-
trophils are inappropriately activated within the circulation, thus 
contributing to vascular injury and thrombosis in COVID-19. 
Exploring the differences in neutrophil responses between 
COVID-19 and non-COVID-19 ARDS provides an opportunity 
to understand the mechanisms common to ARDS and those that 
drive the hypercoagulable hyperinflammatory state specific to 
COVID-19, thus identifying urgently required therapeutic targets.
In this program of work, we compared the blood neutrophil 
populations of patients with COVID-19 ARDS to those of patients 
with non-COVID-19 ARDS, moderate COVID-19 and healthy 
controls to define the neutrophil host response to SARS-CoV-2. 
Prior to SARS-CoV-2, a significant confounder of ARDS 
studies has been the heterogeneity of the underlying processes 
that result in ARDS with hyperinflammatory and hypoinflam-
matory phenotypes described. Infection with SARS-CoV-2 
provides a unifying trigger to this aberrant host response, 
whilst comparison between COVID-19 and non-COVID-19 
ARDS allows us to identify neutrophil responses that are observed 




Human peripheral venous blood was taken from healthy volun-
teers with written informed consent obtained from all partici-
pants prior to sample collection as approved by the University 
of Edinburgh Centre for Inflammation Research Blood Resource 
Management Committee (AMREC 15-HV-013). The collection of 
peripheral venous blood from patients diagnosed with COVID-19 
and/or presenting with ARDS was approved by Scotland A 
Research Ethics Committee (20/SS/0002, 20/SS/0052). Patient 
recruitment took place from April 2020 through January 2021 from 
The Royal Infirmary of Edinburgh, Scotland, UK through the 
ARDS Neut (20/SS/0002) and CASCADE (20/SS/0052) Study, 
with informed consent obtained by proxy. Initial approach was 
made by a member of the clinical care team to participants or 
where participants lacked capacity due to underlying physiologi-
cal compromise to their relative, welfare attorney or legal repre-
sentative. During this initial approach information sheets were 
provided and following consideration, where appropriate separate 
contact made by the research team with either the participant or 
their representative. Individuals were then guided through the 
information sheet details, and formal written consent obtained.
Healthy donor and patient recruitment
The presence of ARDS was defined using the Berlin criteria20. 
Acute physiology and chronic health evaluation (APACHE II) 
score = acute physiology score + age points + chronic health points, 
was undertaken (minimum score = 0; maximum score = 71), 
where increasing score is associated with increasing risk of 
hospital death21. Functional Comorbidity Index data (FCI) was also 
captured as an 18-item list of comorbidities used to adjust for the 
effect on physiological function22. Scores were performed by the 
clinicians responsible for the patients care on intensive care unit 
admission or earliest time possible, and collated at a later date 
by the research team. Nasopharyngeal swabs were undertaken 
at point of hospital admission for all patients included in this 
study. Infection with SARS-CoV-2 was confirmed in the clinical 
hospital laboratories by polymerase chain reaction (PCR) as part 
of routine clinical care. Where initial swab results were negative 
for SARS-CoV-2, but high clinical suspicion remained, deep 
airway samples were obtained at point of intubation and clinical 
testing for SARS-CoV-2 was repeated.
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Isolation of human peripheral blood neutrophils
Up to 80 mL of whole blood was collected into citrate tubes. 
An aliquot of 5 mL of whole blood was treated with red cell 
lysis buffer (Invitrogen) and with the remaining volume, human 
blood leukocytes were isolated by dextran sedimentation 
and discontinuous Percoll gradients as described by Haslett 
et al. (1985)23. Briefly, blood was first centrifuged at 300 × g 
(acceleration 5, deceleration 5) for 20 minutes and the plate-
let-rich plasma layer removed. Erythrocyte sedimentation 
and leukocyte-rich plasma were obtained by incubating the 
remaining contents in the tube with 6 mL of 6% Dextran 
500 (Pharmacosmos) in saline and final volume adjusted to 
50 mL with 0.9% NaCl (Baxter) for at least 20 minutes at room 
temperature. The leukocyte-rich portion was centrifuged at 
350 × g (acceleration 5, deceleration 5) for 6 minutes, with the 
pellet resuspended in 3 mL of 49.5% Percoll (GE Healthcare) 
and overlayed onto 61.2% Percoll and 72.9% Percoll. Gradients 
were centrifuged at 720 × g (acceleration 1, deceleration 0) for 
20 minutes to obtain PMN and PBMC layers.
Cell culture
Normal density neutrophils (NDNs) obtained from the polymor-
phonuclear (PMN) layer of healthy donors were resuspended 
at 5 × 106 cells/mL in Roswell Park Memorial Institute (RPMI) 
1640 (Gibco) with 10% dialyzed foetal calf serum (Gibco) and 
50 U/mL streptomycin and penicillin in normoxia (19 kPa) 
or hypoxia (3 kPa) at 5% CO
2
 as previously described24. 
Briefly, an InvivO
2
 400 hypoxic work-station (BakerRuskinn) 







 was delivered into the chamber 
to achieve oxygen tension of 3 kPa and culture medium 
was equilibrated for at least 4 h prior to use. Cells were 
cultured in the absence or presence of interferon (IFN)α/IFNβ 
(500 units/mL) and/or resiquimod (15 µM, Sigma-Aldrich) for 
the indicated time prior to harvest. For flow cytometry studies 
using dexamethasone and resiquimod, cells were cultured in 
hypoxia and pre-treated with varying doses of dexamethasone 
(0–1 µM) for 4 h, followed by treatment with resiquimod 
(15 µM) for 1 h. For heavy glutamine tracing studies, NDN were 
cultured in the presence of 2 mM U-13C
5
 glutamine (Cambridge). 
For extracellular flux analysis, cells were cultured in the 
presence or absence of interferon in hypoxia as above before 
transfer to an extracellular flux cell culture microplate after three 
hours.
Flow cytometry
Lysed whole blood, PMN and PBMC layers isolated from 
Percoll gradients, as well as healthy control NDN used for 
dexamethasone/resiquimod studies were stained with Zombie 
Aqua™ Fixable viability dye (1:400) (Biolegend) to exclude dead 
cells from analysis. Cells were subsequently treated with Human 
TruStain FcX™ (1:100) (Biolegend) and stained for 30 min on 
ice with antibodies listed in Table 1 with appropriate fluorescence 
minus one (FMO) controls. Cells were then washed and fixed 
with 4% paraformaldehyde (PFA, Fisher Scientific) and acquired 
using BD LSRFortessa™ flow cytometer (Beckton Dickinson). 
Compensation was performed using BD FACSDiva™ soft-
ware version 8.0 and data analysed in FlowJo version 10.2 
(WinMDI is a freely available alternative). Gating strategies to 
identify neutrophils, maturity and surface expression of various 
markers are outlined in Figure 1. Samples with neutrophil purity 
of <95% (CD66b+CD49d-) were excluded from analysis.
Proteomic sample preparation
NDN were centrifuged at 300 × g for 5 min at 4°C and 
resuspended in 7 mL of 0.2% NaCl (w/v in H
2
O) for 5 min 
at room temperature and topped up with 7 mL of 1.6% NaCl 
(w/v in H
2
O). Cells were washed twice in Dulbecco’s phosphate-
buffered saline (DPBS; Thermo Fisher), pelleted at 300 × g for 
5 min at 4°C and resuspended in 372 µL of freshly made 5% 
sodium dodecyl sulfate (SDS, BioRad) lysis buffer and 
vortexed. Samples were then heat denatured in a heat block for 
5 min at 100°C and stored at –80°C. Cell lysates were thawed 
and tris(2-carboxyethyl) phosphine hydrochloride (TCEP) and 
Table 1. List of antibodies used for multi-panel flow cytometry and microscopy. Detailed list of all antibodies used for flow 
cytometry and microscopy staining. Refer to the corresponding method details section for further information.
Antibody Host Class Clone Catalogue number
RRIDs Fluorophore Source Concentration
CD16 Mouse Monoclonal eBioCB16 11-0168-42 AB_10805747 FITC Ebioscience 1:100
CD63 Mouse Monoclonal H5C6 353004 AB_10897809 PE Biolegend 1:100
CD10 Mouse Monoclonal HI10a 312214 AB_2146548 PE-Cy7 Biolegend 1:100
CD66b Mouse Monoclonal G10F5 305114 AB_2566038 AF700 Biolegend 1:100
CD62L Mouse Monoclonal DREG-56 304814 AB_493582 APC-Cy7 Biolegend 1:100
CD11b Rat Monoclonal M1/70 101243 AB_2561373 BV785 Biolegend 1:400
CD49d Mouse Monoclonal 9F10 304322 AB_2563972 BV421 Biolegend 1:100
CD41 Mouse Monoclonal HIP8 303729 AB_2629626 BV421 Biolegend 1:100
CD18 Mouse Monoclonal TS1/18 302117 AB_2565584 PE-Cy7 Biolegend 1:100
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Figure 1. Representative plots of the gating strategy to analyse neutrophil populations. Strategy shown in the direction of the 
arrows. Cells were gated for singlets on a forward scatter height (FSC-H) vs. forward scatter area (FSC-A) plot. Singlets were then gated for 
cells on a side scatter area (SSC-A) vs. FSC-A plot, with non-viable cells excluded according to SSC-A vs. Zombie Aqua Fixable Viability Dye 
parameter. Viable single cells were gated for CD66b+ cells to identify neutrophils and eosinophils excluded according to SSC-A vs. CD49d, 
with fluorescence minus one (FMO) controls used to set gates. CD66b+CD49d- cells (neutrophils) were gated for mature (CD16+) and 
immature (CD16-) neutrophils, with FMO controls used to set gate.
triethylammonium bicarbonate (TEAB) were added to a final 
concentration of 10 mM and 50 mM, respectively. Lysates were 
shaken at 500 rpm at 22°C for 5 min before being incubated 
at 98°C for 5 min. Samples were allowed to cool and were 
then sonicated with a BioRuptor (30 cycles: 30 s on and 30 s 
off). Tubes were centrifuged at 17,000 × g to collect the cell 
lysate and 1 mL of benzonase (27.8 units) was added to each 
sample and samples incubated at 37°C for 15 min. Samples 
were then alkylated with addition of 20 mM iodoacetamide for 
1 h at 22°C in the dark. Protein lysates were processed for 
mass spectrometry using s-trap spin columns following the 
manufacturer’s instructions (Protifi)25. Lysates were digested 
with Trypsin at a ratio 1:20 (protein:enzyme) in 50 mM ammo-
nium bicarbonate. Peptides were eluted from s-trap columns by 
sequentially adding 80 mL of 50 mM ammonium bicarbonate 
followed by 80 mL of 0.2% formic acid with a final elution 
using 80 mL of 50% acetonitrile + 0.2% formic acid.
Liquid chromatography–mass spectrometry (LC-MS) 
analysis
For each sample, 2 mg of peptide was analysed on a 
Q-Exactive-HF-X (Thermo Scientific) mass spectrometer 
coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). 
LC buffers were the following: buffer A (0.1% formic acid in 
Milli-Q water (v/v)) and buffer B (80% acetonitrile and 0.1% 
formic acid in Milli-Q water (v/v)). 2 µg aliquot of each sample 
were loaded at 15 µL/min onto a trap column (100 µm × 2 cm, 
PepMap nanoViper C18 column, 5 µm, 100 Å, Thermo Scientific) 
equilibrated in 0.1% trifluoroacetic acid (TFA). The trap column 
was washed for 3 min at the same flow rate with 0.1% TFA then 
switched in-line with a Thermo Scientific, resolving C18 column 
(75 µm × 50 cm, PepMap RSLC C18 column, 2 µm, 100 Å). 
The peptides were eluted from the column at a constant flow 
rate of 300 nl/min with a linear gradient from 3% buffer B to 
6% buffer B in 5 min, then from 6% buffer B to 35% buffer B in 
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115 min, and finally to 80% buffer B within 7 min. The column 
was then washed with 80% buffer B for 4 min and re-equilibrated 
in 3% buffer B for 15 min. Two blanks were run between each 
sample to reduce carry-over. The column was kept at a constant 
temperature of 50oC at all times.
The data was acquired using an easy spray source operated 
in positive mode with spray voltage at 1.9 kV, the capillary 
temperature at 250°C and the funnel RF at 60°C. The MS 
was operated in data-independent acquisition (DIA) mode 
as reported earlier26 with some modifications. A scan cycle 
comprised a full MS scan (m/z range from 350–1650, with a 
maximum ion injection time of 20 ms, a resolution of 120 000 
and automatic gain control (AGC) value of 5 × 106). MS survey 
scan was followed by MS/MS DIA scan events using the 
following parameters: default charge state of 3, resolution 
30.000, maximum ion injection time 55 ms, AGC 3 × 106, 
stepped normalized collision energy 25.5, 27 and 30, fixed 
first mass 200 m/z. The inclusion list (DIA windows) and 
windows widths are shown in Table 2. Data for both MS and 
MS/MS scans were acquired in profile mode. Mass accuracy 
was checked before the start of samples analysis.
Analysis of proteomics data
The DIA data were analysed with Spectronaut 14 using the 
directDIA option27 (Skyline, MacCoss Lab Software is a freely 
available alternative). Cleavage Rules were set to Trypsin/P, 
Peptide maximum length was set to 52 amino acids, Peptide 
minimum length was set to 7 amino acids and Missed Cleavages 
set to 2. Calibration Mode was set to Automatic. Search criteria 
Table 2. Inclusion list. Mass spectrometry isolation windows for data 
independent acquisition analysis. Refer to the corresponding method 
details section for further information.
Window m/z Isolation window Window m/z
Isolation 
window
1 383.375 66.8 24 670.5 14.5
2 423 13.5 25 684 13.5
3 435 11.5 26 697 13.5
4 446.5 12.5 27 710.5 14.5
5 458 11.5 28 725.5 16.5
6 469 11.5 29 741 15.5
7 480 11.5 30 756.5 16.5
8 490.5 10.5 31 773.5 18.5
9 501 11.5 32 791 17.5
10 512 11.5 33 808.5 18.5
11 523 11.5 34 827 19.5
12 533.5 10.5 35 846.5 20.5
13 544 11.5 36 866.5 20.5
14 554.5 10.5 37 887.5 22.5
15 565 11.5 38 910.5 24.5
16 575.5 10.5 39 935.5 26.5
17 586 11.5 40 962.5 28.5
18 597.5 12.5 41 992 31.5
19 609.5 12.5 42 1025 35.5
20 621.5 12.5 43 1063 41.5
21 633 11.5 44 1108.5 50.5
22 645 13.5 45 1391.625 516.8
23 657.5 12.5
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included carbamidomethylation of cysteine as a fixed modifica-
tion, as well as oxidation of methionine, deamidation of asparag-
ine and glutamine and acetylation (protein N-terminus) as variable 
modifications. The FDR threshold was set to 1% Q-value at both 
the Precursor and Protein level. The single hit definition was to 
Stripped sequence. The directDIA data were searched against the 
human SwissProt database (July 2020) and included isoforms. 
The Major Group Quantity was set to the Sum of peptide quan-
tity and the Minor Group Quantity was set to the Sum of the 
precursor quantity; Cross Run Normalization was disabled. 
Fold changes and P-values were calculated in R utilising the 
bioconductor package LIMMA version 3.728. The Q-values 
provided were generated in R using the “qvalue” package 
version 2.10.0. Estimates of protein copy numbers per cell were 
calculated using the histone ruler method29. The mass of indi-
vidual proteins was estimated using the following formula: 
CN × MW/NA = protein mass (g cell−1), where CN is the 
protein copy number, MW is the protein molecular weight 
(in Da) and NA is Avogadro’s Constant.
Raw mass spectrometry data files and Spectronaut analysis 
files have been deposited to the ProteomeXchange30 Consortium 
via the PRIDE31 partner repository with the dataset identifier 
PXD023834.
Cell immunostaining for microscopy
PMN and PBMC layers isolated from Percoll gradients 
were fixed with 1.5 % PFA (Fisher Scientific). Fluorescence-
activated cell sorting (FACS) of NDN and LDN from PMN 
and PBMC layers, respectively, were performed using BD 
FACSAria™ Fusion flow cytometer fitted with a 70 µm nozzle 
and running BD FACSDiva™ software version 8.0 (Beckton 
Dickinson). Singlets were gated according to forward scatter 
height vs. forward scatter area (FSC-H vs. FSC-A) and side 
scatter height vs. side scatter area (SSC-H vs. SSC-A) param-
eters and NDN and LDN identified according to forward 
vs. side scatter (FSC vs. SSC) parameters. NDN and LDN 
were collected at 4°C in 15 mL Falcon tubes pre-coated with 
DPBS (Thermo Fisher).
Cells were pelleted and blocked with Fc Receptor Blocking 
Solution followed by staining with anti-CD41 antibody 
(Biolegend) and counterstaining with propidium iodide 
(Biolegend) according to manufacturer’s guidelines. Multichamber 
slides (Ibidi) were used to image the samples in a confocal 
microscope (Leica SP8). Image acquisition was performed at 
63x magnification with the same settings across all images. Fiji 
software was used to process the images32. Scale bars depict 5 µm.
Measurement of granule protein levels
Enzyme-linked immunosorbent assay (ELISA) was performed 
according to manufacturer’s protocol to quantify myeloperoxidase 
(MPO) (Abcam, ab119605), lactoferrin (Abcam, ab108882) 
and elastase levels (Abcam, ab119553) in plasma from healthy 
donors, non-COVID-19 ARDS, COVID-19 patients and cell 
media supernatant of resiquimod treated NDN cultures from 
healthy donors (15 µM, Sigma-Aldrich). Briefly, a standard curve 
with known concentrations of the corresponding enzymes was 
generated to obtain their equivalent optical densities in a 
colorimetric assay. The concentration of the relevant enzymes in 
each sample was inferred from their optical densities by using 
the standard curve.
Metabolomic analysis
2.5 × 106 neutrophils freshly isolated from the PMN layer of 
patients were centrifuged at 300 × g for 5 min at 4°C, with 
pellets resuspended in 100 µL of 80% methanol. Alternatively, 
5 × 106 NDN from healthy controls were cultured in hypoxia 
for 4 h in the presence or absence of IFNα/IFNβ, washed twice 
in ice cold saline following culture and lysed in 200 µL of 
50:30:20 methanol:acetonitrile:water. Following extraction, sam-
ples were stored at –80°C. Relative metabolite abundance was 
determined using ion-pairing reverse phase high performance 
liquid chromatography (RP-HPLC) or hydrophilic interaction 
liquid chromatography coupled to a Q-exactive Orbitrap Mass 
Spectrometer. Data were analysed in a targeted manner, using 
Xcalibur (Thermofisher Scientific) against an in-house compound 
library to integrate the area under the curve at the expected reten-
tion time. Individual metabolites were expressed relative to the 
mean of the healthy control population and analysed in Prism 
9.00 (Graphpad Software Inc).
Extracellular flux analysis
After culture, cells were harvested into sealed Eppendorfs and 
maintained in hypoxia for one wash in warm saline. Cells were 
resuspended at 3 × 106/mL in XF DMEM pH 7.4 (Agilent), 
supplemented with 2 mM glutamine and IFNα/IFNβ added to 
the appropriate cells at the concentrations described previously. 
3 × 106 neutrophils were adhered into each well of a 24-well 
cell culture microplate (Agilent) pretreated with cell-tak 
(Corning) to give triplicate samples per condition with four 
wells left as media controls. After allowing CO
2
 to degas for 
45 min in a hypoxic incubator, the plate was loaded into a 





; SCI-tive hypoxic workstation, 
Baker Russkinn). Treatment compounds were resuspended in 
XF DMEM and cells were sequentially treated by injection of 
resiquimod (15 µM), glucose (10 mM, Sigma), oligomycin A 
(1 µM, Sigma) and 2-deoxyglucose (50 mM, Sigma). All media 
and compounds were pre-equilibrated in hypoxia. Data were 
acquired using Seahorse Wave Controller (version 2.6, Agilent) 
and analysed using Wave before exporting to GraphPad to pool 
for final analysis.
Statistical analyses
Statistical tests were performed using Prism 9.00 software 
(GraphPad Software Inc). Data were tested for normality using 
Shapiro-Wilk test and outliers excluded according to Grubb’s test, 
with significance testing detailed in figure legends. Significance 
was defined as a p value of <0.05 after correction for multiple 
comparisons where applicable. Sample sizes are shown in figure 
legends, with each n number representing a different donor.
An earlier version of this article can be found on medRxiv 
(doi: https://doi.org/10.1101/2020.09.15.20195305).
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Results
Study population cohorts
To define the circulating neutrophil response to infection with 
SARS-CoV-2 we studied peripheral blood neutrophil popu-
lations isolated from hospitalised patients with moderate 
COVID-19 and COVID-19 ARDS, comparing these to critical care 
patients with non-COVID-19 ARDS and healthy controls (male, 
n = 4; female, n = 5; age range: 20 – 50 years) (Figure 2A)33. 
Patient demographic details are provided in Table 3. In accord-
ance with the WHO COVID-19 classification, patients recruited 
had either moderate (clinical signs of pneumonia with oxygen 
saturations >90%) or critical (ARDS) COVID-1934. Patients 
with Berlin criteria ARDS had mean APACHE II scores of 18.1 
(non-COVID-19) and 14.8 (COVID-19), respectively. Viral 
infections were excluded from the aetiology of non-COVID-19 
ARDS. Of the 12 patients recruited with COVID-19 ARDS, 
nine received dexamethasone. 
Circulating neutrophil populations are expanded in 
COVID-19 and non-COVID-19 ARDS
To explore the different neutrophil populations, flow cytometry 
analysis of whole blood was first performed to identify 
CD66b+ cells as neutrophils, with CD16 used as a marker of matu-
rity. CD66b+CD16+ and CD66b+CD16- cells were observed, 
indicating the presence of a heterogenous population of mature 
and immature neutrophils in ARDS patients, regardless of 
COVID-19 status (Figure 2B). Given immature neutrophils are 
characteristically low-density neutrophils (LDN) and associated 
with disease35, flow cytometry analysis was performed on PMN 
and PBMC layers isolated using Percoll density gradients. Further 
characterisation of neutrophil maturity was undertaken by CD10 
expression and showed both a mature (CD66b+CD16+CD10+) 
and immature (CD66b+CD16-CD10-) LDN population in the 
PBMC layer of non-COVID-19 and COVID-19 ARDS patients 
(Figure 2C). In contrast, these populations are notably absent 
in the PBMC layer of healthy control individuals (Figure 2C). 
Importantly, these LDN populations demonstrated evidence 
of increased activation states with loss of CD62L (Figure 2D), 
and upregulation of both CD66b and CD63 (Figure 2E–F). 
Total neutrophil counts generated from Percoll preparations 
showed a large expansion of neutrophils in ARDS (Figure 2G). 
Though a major proportion of the neutrophil population consisted 
of mature NDN from the PMN layer, we detected the presence 
of immature and mature low density neutrophil populations in 
ARDS patients (Figure 2H). Of note, the increase in immature 
LDN in the COVID-19 ARDS cohort was significantly reduced 
in those receiving dexamethasone despite a retained expansion of 
NDN and mature LDN populations (Figure 2H).
Circulating neutrophils restructure their proteomes 
whilst retaining global cellular processes in COVID-19 
and non-COVID-19 ARDS
A growing body of studies have described a disordered myeloid 
response following infection with SARS-CoV-2 using single cell 
RNA sequencing (scRNA-seq). These studies provide important 
insights to the reprogramming of myelopoiesis and the 
emergence of precursor neutrophil populations. However, there 
is a real need to understand how these transcriptional signatures 
relate to functional changes in myeloid cell responses, which 
requires information at a protein level. To understand changes 
in the functional proteome of circulating neutrophils we used 
a label free DIA mass spectrometry approach. Estimates of 
protein copy numbers per cell were calculated using the histone 
ruler method29, along with total cellular protein content and 
the mass of subcellular compartments. We compared protein 
abundance between non-COVID-19 ARDS, COVID-19 ARDS 
and healthy control neutrophil populations. Analysis of the 
NDN populations common to both healthy control and ARDS 
identified around 4500 proteins (Figure 3A), with a subtle 
reduction in the total protein content of COVID-19 ARDS 
neutrophils (Figure 3B). We observed preservation of global 
cellular processes across all disease groups evidenced by 
equivalent mitochondrial protein content, ribosomal protein 
content, nuclear envelope protein abundance and cytoskeletal 
protein abundance (Figure 3C). Key components of the trans-
lation initiation complex were also conserved across health 
and disease groups (Figure 3D). This would suggest that any 
differences observed in key neutrophil functions are not driven 
by a loss of core cellular processes and, therefore, more likely 
to be consequent upon activation of signalling pathways in 
response to infectious and inflammatory challenges. Globally we 
only detected a small number of proteins involved in transcrip-
tion factor activity whose abundance was modified in response to 
COVID-19 (Figure 3E). These included the interferon regulated 
proteins TRIM22 and STAT1, which were induced in COVID-19 
ARDS neutrophils and the glucocorticoid receptor NR3C1 
which was down regulated.
To determine which components of the neutrophil proteome 
remodel in patients with COVID-19 and non-COVID-19 
ARDS we undertook Linear Models for Microarray data (LIMMA) 
analysis to identify significant differences in protein abun-
dance (data are available via ProteomeXchange with identifier 
PXD023834). We identified more than 200 proteins to be 
increased in abundance between COVID-19 ARDS and healthy 
control neutrophils which were not significantly changing in 
non-COVID ARDS (Figure 4A–B). Gene ontology (GO) 
term enrichment analysis of these differentially regulated 
proteins identified a COVID-19 signature which was defined 
by a greater abundance of proteins in type I IFN signalling 
pathways and platelet degranulation (Figure 4B). Change in 
expression of cullin 2, cyclin dependent kinase 2, minichromo-
some maintenance complex components (MCM3-5 and MCM7) 
and phosphoribosyl pyrophosphate amidotransferase, proteins 
associated in other cell types with cell cycle control, was com-
mon to both COVID-19 and non-COVID-19 ARDS, whilst 
proteins important for mitochondrial translational termination 
and cell surface receptor signalling pathways were enriched in 
non-COVID-19 ARDS samples (Figure 4B). We identified 115 
proteins with reduced abundance in ARDS (all cause) versus 
healthy control neutrophils, including some proteins that were 
specific to COVID-19. However, distinct biological processes 
impacted by SARS-CoV-2 infection were not identified 
among those proteins with reduced abundance.
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Figure 2. Circulating neutrophil populations are expanded in COVID-19 and non-COVID-19 ARDS. (A) Patient classification (healthy 
control, HC, non-COVID-19 ARDS, NA, moderate COVID-19, MC, and COVID-19 ARDS, CA), neutrophil isolation, and workflow depicted. 
(B) Representative side scatter (SSC) vs. forward scatter (FSC) plots of stained whole blood from HC, NA and CA displaying lymphocyte 
(green), monocyte (pink), mature (CD16+, orange) and immature (CD16-, blue) neutrophil populations. (C) Representative CD16 vs. CD10 
dot plots of stained polymorphonuclear (PMN) and peripheral blood mononuclear cell (PBMC) layers isolated by Percoll gradients from HC 
(grey), NA (blue) or CA (pink) patients, with quadrant2 (Q2) delimiting the CD16+CD10+ (mature neutrophils) area. (D–F) Surface expression 
of neutrophil activation markers expressed as a fold change of geometric mean fluorescence intensity (MFI) from normal density neutrophils 
(NDN) respective to the disease state as determined by flow cytometry analysis of mature NDN (CD66b+CD16+, open bars), mature low 
density neutrophils (LDN) (CD66b+CD16+, horizontal striped bars) and immature LDN (CD66b+CD16-, vertical striped bars) from NA (n = 
5), MC (n = 3), or COVID-19 (n = 11; open circles, dexamethasone treated patients) patients. Data are mean ± SD. *p < 0.05, determined 
by repeated two-way ANOVA and Sidak’s post hoc-testing. (G) Total neutrophil counts of HC (n = 8), NA (n = 5), MC (n=3) and CA (n = 11) 
performed by haemocytometer and differential cell count established by flow cytometry. Data are mean ± SD. ****p < 0.0001, determined 
by one-way ANOVA and Holm-Sidak’s post hoc-testing. (H) The proportion of mature (CD66b+CD16+CD10+, grey bars) and immature 
(CD66b+CD16-CD10-, white bars) LDN isolated from patient cohorts as described in (G), with CA patients treated with dexamethasone as 
CD, were measured by flow cytometry. Data are mean ± SD. *p < 0.05, ***p < 0.001, determined by repeated measures two-way ANOVA 
and Sidak’s post hoc-testing.
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Table 3. Characteristics of study groups. For disease groups, all measurements were taken at the time of trial 
sample unless otherwise specified. Plus-minus values are means ± SD. ‡ For COVID-19 ARDS group, data provided 
for nine patients that were receiving invasive mechanical ventilation (n=8) or non-invasive ventilation (n=1) at the 
time of the sample. The three other patients were receiving high flow nasal oxygen at the time of the sample, so 
these measurements were not available. ARDS: acute respiratory distress syndrome; APACHE II: acute physiology and 
chronic health evaluation II; FCI: Functional Comorbidity Index; ICU: intensive care unit; PaO2: arterial partial pressure 
of oxygen; SpO2: peripheral oxygen saturation; PEEP: positive end-expiratory pressure.






Age – yr 48.7±9.3 59.0±14.5 85.7±5.7
Female sex – no. (%) 5 (71.4) 3 (25.0) 2 (66.7)
Body-mass index – kg/m2 27.7±2.9 33.1±8.5 19.9±3.3
Clinical data
Cause of ARDS
Pulmonary – no. (%) 5 (71.4) 12 (100.0)
Extra-pulmonary 2 (28.6) 0 (0.0)
APACHE II Score 18.1±5.4 14.8±3.9
Functional Comorbidity Index 1.4±0.8 1±0.7
Lowest SpO2 in 6 hrs prior to ICU 
admission 89.4±6.0 77±21
Organ injury and support
Invasive mechanical ventilation – no. (%) 7 (100.0) 8 (66.7)
Renal replacement therapy – no. (%) 1 0
Vasopressors – no. (%) 7 (100.0) 4 (33.3)
ARDS Therapy‡
Peak pressure (cmH2O) 25.0±7.2 24±6
PEEP (cmH2O) 7.9±3.2 10±4
Tidal volume (ml) 366.0±59.5 402±63
Respiratory rate (breaths/min) 28.12±2.3 23.1±3.8
Medications
Lopinavir-Ritonavir – no. (%) 0 (0.0) 3 (25.0) 0 (0.0)
Hydroxychloroquine – no. (%) 0 (0.0) 2 (16.7) 0 (0.0)
Dexamethasone – no. (%) 0 (0.0) 9 (75.0) 0 (0.0)
COVID-19 ARDS neutrophils form aggregates with 
platelets and activate prothrombotic pathways
A striking clinical and post-mortem observation in patients 
with COVID-19 is the prevalence of micro and macrovascular 
thrombosis. With previous evidence of NET formation18,19, 
together with the colocalization of neutrophils with platelets in 
fibrin rich clots and our identification of a platelet degranulation 
signature within the COVID-19 ARDS samples, this led us to 
question the mechanism by which neutrophils could be 
contributing to immune mediated thrombosis in COVID-19. NDN 
displayed an overall increase in proteins associated with fibrin 
clot formation; fibrinogen alpha, fibrinogen beta and coagulation 
factor XIII alpha chain (F13A1) and a failure to induce proteins 
that inhibit fibrin clot formation in NDN like antithrombin-III 
(Figure 5A). This signature was greatest in COVID-19 ARDS 
neutrophils (Figure 5A). We also detected a platelet protein 
signature indicated by the presence of the platelet proteins 
platelet factor 4, platelet basic protein (Figure 5B). Confocal 
imaging on sorted mature neutrophil populations from 
COVID-19 ARDS patients subsequently revealed the existence 
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Figure 3. Circulating neutrophils preserve global cellular processes in both COVID-19 and non-COVID-19 ARDS. (A) Number of 
proteins identified by proteomic analysis in normal density neutrophils (NDN) isolated from healthy controls (HC, n = 4), non-COVID-19 
ARDS patients (NA, n = 6) and COVID-19 ARDS patients (CA, n = 7), with open circles depicting the data corresponding to dexamethasone-
treated patients. Refer to methods section for details. Data are mean ± SD. (B–C) Total protein content, protein content of mitochondria 
(GO:0005739), ribosomes (Kyoto Encyclopaedia of Genes and Genomes annotation 03010), nuclear envelope (GO:0005635) and cytoskeleton 
(GO:0005856) in the same samples described in (A) determined by proteomic analysis. Data as mean ± SD. (D) Abundance of components 
of the eIF4F translation initiation complex (figure adapted from Howden et al. 201936) in the same samples described in (A) determined by 
proteomic analysis. Data as mean ± SD. (E) Volcano plots reflecting the expression profile of transcription factors in the samples from CA 
vs. HC, and NA vs. ARDS depicted in (A) after proteomic analysis. Proteins were included with the annotation GO:0003700 (DNA binding 
transcription factor activity). Horizontal dashed line indicates a P value = 0.05, outer vertical dashed lines indicate a fold change = 2. P values 
calculated using Linear Models for Microarray data analysis. The DNA binding transcription factor proteins TRIM22, STAT1 and NR3C1 are 
highlighted.
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Figure 4. Specific proteome remodelling in circulating neutrophils in response to COVID-19 ARDS and ARDS. (A) Volcano plots 
obtained from proteomic survey of normal density neutrophils (NDN) isolated from healthy controls (HC, n = 4), non-COVID-19 ARDS patients 
(NA, n = 6) and COVID-19 ARDS patients (CA, n = 7). Refer to methods section for details. Proteins with a P value <0.05 (horizontal dashed 
lines), fold change >2 (outer vertical dashed lines) and a copy number >200 in at least one condition after Linear Models for Microarray data 
analysis were considered as significantly different in the comparisons CA vs HC (left) and NA vs HC (right). (B) GO term enrichment analysis 
for proteins significantly increased in abundance in CA and NA patients vs HC. Venn diagram shows the numbers of proteins uniquely 
increased in abundance in CA and NA and also the number of proteins shared between these two groups. A selection of the top enriched 
GO terms and the corresponding proteins are shown.
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Figure 5. COVID-19 ARDS neutrophils form aggregates with platelets and activate prothrombotic pathways. (A) Copy 
numbers of proteins that regulated fibrin clot formation in normal density neutrophils (NDN) isolated from healthy controls (HC, n = 3–4), 
non-COVID-19 ARDS (NA, n = 4–6), and COVID-19 ARDS (CA, n = 7, with open circles depicting the data corresponding to dexamethasone-
treated patients) patients determined by proteomic analysis. For fibrinogen alpha, fibrinogen beta and antithrombin-III, data as mean ± 
SD, *p < 0.05, determined by Kruskal-Wallis and Dunn’s post hoc-testing. For coagulation factor XIII alpha chain (F13A), data as mean ± SD. 
(B) Copy numbers of proteins associated with platelets in the same samples described in (A) determined by proteomic analysis. Data as mean 
± SD. (C) Representative confocal images from NDN obtained from a healthy donor and LDN from a CA patient isolated by fluorescence-
activated cell sorting (FACS) and stained for propidium iodide (top left panel, red) and CD41 (top right panel, green). Bright field image was 
used to delimit cell contour (bottom left panel, grey scale). A composite image is shown in bottom right panel. Scale bar corresponds to 
5 μm, 63x magnification. (D) Percentage of NDN (open bars), mature LDN (horizontal striped bars) and immature LDN (vertical striped 
bars) isolated from HC (n = 6–7), NA (n = 3–5), MC (n = 3) or CA patients (n = 8-11; open circles depict dexamethasone treated patients) with 
surface expression of CD41. Data are median ± I.Q.R. *p < 0.05, ****p < 0.0001 vs. HC, determined be Kruskal-Wallis and Dunn’s post hoc-
testing. (E) Surface expression of CD11b and CD18 (Mac-1 complex) displayed as geometric mean fluorescence intensity (MFI) determined 
by flow cytometry analysis of neutrophil populations described in (D). Data are mean ± SD. **p < 0.01, ***p < 0.001, determined by repeated 
measures two-way ANOVA and Sidak’s post hoc-testing; *p < 0.05, **p < 0.01 vs. HC, determined be one-way ANOVA and Holm-Sidak’s 
post hoc-testing. (F) Surface expression of CD11b and CD18 (Mac-1 complex) expressed as a fold change of MFI of HC NDN cultured under 
untreated normoxic conditions (N–U) determined by flow cytometry analysis of HC NDN cultures in hypoxia under untreated conditions 
(H–U) or with varying doses of dexamethasone for 3 h and follow-up treatment with resiquimod for 1 h. Data are mean ± SD (n = 3–5). 
*p < 0.05, determined by repeated measures one-way ANOVA and Holm-Sidak’s post hoc-testing.
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of a direct physical association between LDN and platelets in 
these patients, as opposed to neutrophils from healthy donors 
(Figure 5C). To understand how neutrophil platelet aggregates 
were forming we looked for evidence of platelet activation on 
the neutrophil surface, and neutrophil expression of adhesion 
molecules involved in platelet interactions. Initial measurements 
for expression of CD41, a marker of platelet activation, revealed 
the presence of CD41 on mature LDN isolated from COVID-19 
patients (Figure 5D). This coincided with a significant increase 
in mature neutrophil expression of the CD11b component of the 
Mac-1 platelet binding complex (Figure 5E). This phenotype 
was specific to the mature neutrophil populations, with only 
low-level surface expression of CD41, CD18, CD11b observed 
in the immature LDN population (Figure 5D-E).
Toll like receptors (TLRs) are important for viral recognition 
by the innate immune response. TLR family members 7 and 8 
have been previously reported to enable recognition of single 
stranded RNA viruses including influenza and SARS-CoV-237,38. 
To directly address whether neutrophil sensing of SARS-CoV-2 
RNA was important for the regulation of Mac-1, we stimu-
lated healthy control neutrophils with TLR 7 and 8 agonist 
resiquimod39. Additionally, hypoxic culture conditions were used 
to replicate the systemic hypoxia that circulating neutrophils 
are exposed to in patients with COVID-19 ARDS. Resiquimod 
up-regulated neutrophil expression of both components of the 
Mac-1 platelet binding complex, CD11b and CD18 (Figure 5F) 
replicating the observed phenotype of COVID-19. In keeping with 
the patient data, the addition of dexamethasone to resiquimod 
stimulation did not impact CD11b or CD18 expression 
(Figure 5F).
The presence of neutrophil platelet aggregates in patients with 
COVID-19 ARDS led us to question why neutrophils were 
binding to activated platelets, and whether there was evidence 
that neutrophils themselves were becoming inappropriately 
activated in the blood. Neutrophils express a plethora of cell 
surface receptors to enable them to respond to noxious stimuli. 
A key element of this response is the highly regulated release 
of cytotoxic granule proteins. However, inappropriate degran-
ulation in the lung tissue during ARDS is associated with 
epithelial and vascular damage which in turn potentiates lung 
injury40. In health, the release of toxic granules by neutrophils 
in the circulation is limited by the requirement of a second 
activation stimulus following neutrophil priming41. Comparison 
of the proteomes of NDN populations revealed that granule 
cargo proteins are highly abundant and account for approxi-
mately 20% of the neutrophil protein mass (Figure 6A). In 
both COVID-19 and non-COVID-19 ARDS, whilst we 
observed an equivalent abundance of primary (CD63, CD68 and 
Presenilin-1), secondary (Ras related proteins 1A-B and 
2A-C), secondary and tertiary (secretory carrier membrane 
protein 1–4, vesicle associated membrane protein 2) and spe-
cifically tertiary (solute carrier 11A1) granule membrane proteins 
(data are available via ProteomeXchange with identifier 
PXD023834), there is a relative reduction in the abundance 
of the granule cargo proteins within these circulating cells 
(Figure 6B). Survey of these individual proteases reveals these 
changes to be modest, but to occur across the different granule 
compartments and to be amplified in COVID-19 (Figure 6C–J). 
To address whether this relative reduction in intra-cellular granule 
protein content was consequent upon neutrophil degranula-
tion, we quantified surface expression of CD63, a protein 
known to be externalised upon degranulation, and CD66b, 
whose surface expression augments in response to degranula-
tion. We observed a significant increase in CD63 and CD66b 
expression which was specific to the COVID-19 ARDS 
neutrophils (Figure 6K). Importantly an increase in serum 
levels of the neutrophil granule proteins MPO, lactoferrin and 
elastase in the COVID-19 ARDS patient cohort (Figure 6L) 
confirmed a phenotype of enhanced circulating neutrophil 
degranulation in the COVID-19 ARDS patient cohort, which 
was not impacted by dexamethasone (Figure 6M). Consistent 
with neutrophil sensing of SARS-CoV-2 RNA promoting 
activation and degranulation, stimulation of healthy control 
neutrophils with the TLR7 and 8 agonist resiquimod increased 
neutrophil shedding of CD62L and upregulated expression of 
CD66b and CD63 (Figure 6N). This resulted in an increase in 
detectable levels of the granule proteins MPO and lactoferrin 
in the cell culture supernatants (Figure 6O).
Activation of neutrophil type I interferon signalling 
pathways and antigen presentation in COVID-19
Type I IFN are a group of cytokines which characterise the 
anti-viral response but are also implicated in inflammatory 
disease and in malignancy. Persistent high levels of circulating 
type I IFN are associated with more severe disease in the late 
stages of disease42, thought to be due to dysfunctional inflam-
mation rather than uncontrolled viral infection. This complexity 
is further reflected in the divergent signals in IFN stimulated 
genes (ISG) described in whole blood and PBMC myeloid cell 
populations, where select changes in transcript abundance are 
used to identify specific cell clusters14. Here, we report using 
LIMMA analysis of NDN proteomes a type I IFN signature 
within the COVID-19 ARDS neutrophils (Figure 4B). We 
therefore surveyed the abundance of proteins involved in 
anti-viral responses downstream of IFNα/β receptor (IFNAR). 
This revealed across the pathway a greater abundance of proteins 
important for type I IFN signalling and anti-viral responses in 
COVID-19 ARDS neutrophils including 2’,5’-oligoadenylate 
synthetase proteins which activate RNase L (Figure 7A), 
Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 
(EIF2AK) which inhibits viral transcription (Figure 7B) and 
the GTP binding Mx proteins which inhibit viral replication 
(Figure 7C).
Another important effect of IFN signalling in viral infection 
is to stimulate antigen presentation of intracellular (i.e. viral) 
antigens via the proteosome to alert T-cells to the infected cell. 
Analysis of the antigen presentation and processing pathway 
showed preserved levels of the immunoproteasome subunits in 
COVID-19 neutrophils (Figure 7D), but a global increase in the 
expression of proteins implicated in immune cell development, 
regulation, antigen processing and presentation (Figure 7E). 
These included a greater copy number of the Transporter 
Associated with Antigen Processing (TAP) proteins required for 
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Figure 6. Enhanced circulating neutrophil degranulation in COVID-19. (A) Pie charts show distribution of protein mass for proteins 
integrating primary, secondary or tertiary granules in healthy control (HC, n = 4), non-COVID-19 ARDS (NA, n = 6) and COVID-19 ARDS (CA, 
n = 7) patients. Data obtained from proteomic analysis of normal density neutrophils (NDN). (B) Membrane (grey bars) and content (white 
bars) granule cargo protein abundance in NDN isolated from the samples described in (A). Data are mean ± SD. *p < 0.05, determined by 
two-way ANOVA and Tukey’s post hoc-testing. (C–J) Copy numbers of granule proteins in the samples described in (A, open circles depict 
dexamethasone-treated patients). For (C–E), data are mean ± SD. For (F–J), data are mean ± SD. **p < 0.01, determined be one-way ANOVA 
and Holm-Sidak’s post hoc-testing. (K) Surface expression of CD63 and CD66b displayed as mean fluorescence intensity (MFI) determined 
by flow cytometry analysis of NDN isolated from HC (n = 7), NA (n = 5), moderate COVID-19 (MC, n = 3) and CA (n = 12, open circles depict 
dexamethasone-treated patients) patients. For CD63, data are mean ± SD. **p < 0.01, ***p < 0.001, determined be one-way ANOVA and 
Holm-Sidak’s post hoc-testing. For CD66b, data are median ± I.Q.R. *p < 0.05, **p < 0.01, determined by Kruskal-Wallis and Dunn’s post 
hoc-testing. (L) Granule protein levels in serum of NA (n = 6), and CA (n = 3) patients measured by ELISA represented as a fold change from 
HC. For myeloperoxidase (MPO), data are median ± I.Q.R. *p < 0.05, determined by Mann-Whitney test. For elastase, data are mean ± SD. 
*p < 0.05, determined by unpaired t-test. (M) Granule protein levels in serum of CA (n = 3), and COVID-19 ARDS dexamethasone-treated 
(CD, n = 5) patients measured by ELISA represented as a fold change from CA. For MPO and lactoferrin, data are mean ± SD. For elastase, 
data are median ± I.Q.R. (N) Surface expression of activation markers expressed as a fold change of MFI of HC NDN under untreated 
normoxic conditions (N–U) determined by flow cytometry analysis of HC NDN cultures in hypoxia under untreated conditions (H–U) or 
with resiquimod (H–R) for 1 h. Data are mean ± SD. *p < 0.05, **p < 0.01, determined by paired one-tailed t-test. (O) Granule protein levels 
measured in H-U and H-R HC NDN culture supernatants at 4 h by ELISA expressed as a fold change of a N-U group. Data are mean ± SD. 
*p < 0.05, determined by paired t-test.
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Figure 7. Activation of neutrophil type I interferon signalling pathways and antigen presentation in COVID-19. (A) Copy numbers 
of 2’,5’-oligoadenylate synthetase (OAS) proteins involved in type I IFN signalling and anti-viral responses in normal density neutrophils 
(NDN) isolated from healthy controls (HC, n = 4), non-COVID-19 ARDS (NA, n = 6) and COVID-19 ARDS (CA, n = 7, open circles depicting 
dexamethasone-treated patients) patients determined by proteomic analysis. Data are mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, 
determined by one-way ANOVA and Holm-Sidak’s post hoc-testing. (B) Copy numbers of EIF2AK in the same samples described in (A). Data 
are mean ± SD. *p < 0.05, determined by Kruskal-Wallis and Dunn’s post hoc-testing. (C) Copy numbers of Mx proteins in the same samples 
described in (A). Data are mean ± SD. *p < 0.05, **p < 0.01, determined by one-way ANOVA and Holm-Sidak’s post hoc-testing. (D) Copy 
numbers of PSMB proteins in the same samples described in (A). Data are mean ± SD. (E) Volcano plots (left) obtained from proteomic 
survey of normal density neutrophils (NDN) isolated from the samples described in (A) including a selection of proteins implicated in antigen 
processing and presentation and interferon signalling (GO:0002376) highlighted in red and with some of them labelled as illustrative 
examples. Refer to methods section for details. Proteins with a P value <0.05 (horizontal dashed lines), fold change >2 (outer vertical dashed 
lines) and a copy number >200 in at least one condition after Linear Models for Microarray data analysis were considered as significantly 
different in the comparisons CA vs HC (top) and NA vs HC (bottom). Table (right) includes a selection of proteins from the samples described 
in (A) involved in antigen processing and presentation or interferon signalling which significantly change in abundance in CA vs. HC (>2 fold 
change, p<0.05). Proteins highlighted in red show a COVID-19 specific signature and did not significantly change in non-COVID-19 ARDS 
alone. Mean copy numbers are shown. (F) Copy numbers of Transporter Associated with Antigen Processing (TAP) proteins in the same 
samples described in (A). For TAP-1, data are mean ± SD. **p < 0.01, determined by one-way ANOVA and Holm-Sidak’s post hoc-testing. For 
TAP-2, data are mean ± SD. *p < 0.05, **p < 0.01, determined by Kruskal-Wallis and Dunn’s post hoc-testing. (G) Copy numbers of major 
histocompatibility complex molecules in the same samples described in (A). Data are mean ± SD. *p < 0.05, **p < 0.01 determined by one-
way ANOVA and Holm-Sidak’s post hoc-testing.
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transport into the endoplasmic reticulum for loading onto class I 
major histocompatibility complex (MHC) molecules (Figure 7F), 
and in class I MHC molecules themselves (Figure 7G).
ARDS neutrophils and type I interferon stimulated 
healthy neutrophils have altered metabolic profiles with 
enhanced glutamine utilisation
Type I IFNs have been found to drive metabolic adaptations 
in plasmacytoid dendritic cells (pDC) with upregulation of fatty 
acid oxidation and oxidative phosphorylation promoting pDC 
activation in response to TLR 9 agonists43. To address whether 
neutrophils have the capacity to adapt their metabolic programs 
in response to type I IFN or TLR 7 and 8 activation, blood neu-
trophils from healthy controls were stimulated in the presence or 
absence of resiquimod, IFNα and IFNβ and glycolysis was assessed 
by extracellular flux analysis (Figure 8A). Resiquimod induced a 
significant uplift in glycolysis and glycolytic capacity, which was 
partially abrogated by the addition of type I IFNs (Figure 8A). 
To further characterise the metabolic rewiring in response to 
type I IFN we undertook LC-MS quantification of individual 
metabolic intermediaries. In keeping with the real time reduc-
tion in extracellular acidification rates, IFN treated neutrophils 
showed a reduced lactate content (Figure 8B). This was 
associated with preservation of TCA cycle intermediaires 
including citrate, alphaketoglutarate, malate and succinate 
(Figure 8C) and a significant increase in the amino acid gluta-
mate (Figure 8D). Together with (U)-13C
5
 glutamine tracing 
into glutamate this would support the ability of neutrophils to 
substrate switch in response to exposure to type I IFN 
(Figure 8E). To address whether this metabolic rewiring was 
observed in blood neutrophils isolated from patients with COVID-
19 and non-COVID-19 ARDS we undertook LC-MS analy-
sis of freshly isolated cells. In contrast to type I IFN stimulation 
of healthy control neutrophils, neutrophils from COVID-19 and 
non-COVID-19 ARDS patients demonstrated an increase in 
intracellular levels of free glucose (Figure 8F) while preserving 
their lactate content (Figure 8G) and TCA cycle intermediaries 
(Figure 8H) compared to healthy control neutrophils, suggesting 
these cells have equivalent glycolytic flux and TCA cycle activ-
ity. However, in keeping with the capacity of ARDS neutrophils 
to substrate switch, glutamate levels were elevated in both 
COVID-19 and non-COVID ARDS neutrophils (Figure 8I).
Discussion
ARDS continues to result in significant mortality despite 
considerable research endeavour. The emergence of SARS-CoV-
2 infection has confounded this, with 10–20% of hospitalised 
patients progressing to ARDS44. Urgent understanding of the 
immunological features specific to COVID-19 ARDS is there-
fore required. Moreover, the pathophysiological consequences of 
myeloid dysfunction as determined by scRNA-seq, mass flow 
cytometry and blood count studies is as yet unclear, as is the 
mechanism by which dexamethasone improves clinical outcomes 
in COVID-19 ARDS14,42,45,46. We therefore employed flow cytom-
etry and mass spectrometry to characterise disease specific protein 
and metabolite signatures in ARDS neutrophil populations and 
explored their functional implications. Using this approach, 
we identify that the expansion of low density and normal 
density neutrophil populations previously observed in COVID-19 
is also observed in non-COVID-19 ARDS. Whilst total cell 
counts are retained in patients receiving dexamethasone ther-
apy, we report an associated contraction of immature LDN 
neutrophil populations. It will be important to understand 
moving forwards whether a key therapeutic effect of dexam-
ethasone is the suppression of acute myelopoiesis in response 
to infection with SARS-CoV-2.
Proteomic survey also allowed us to highlight key processes, 
including activation of type I IFN responses that are distinct to 
COVID-19 ARDS, but more notably, processes not previously 
detected by scRNA-seq including platelet degranulation and the 
expression of proteins implicated in immune cell development, 
regulation, antigen processing and presentation. Importantly, 
these protein signatures were observed within mature NDN, 
suggesting this not to be a consequence of disordered myelo-
poiesis. It is interesting to note that MCM proteins, that are 
responsible for the separation of DNA and as such are con-
ventionally associated with DNA replication, were enriched in 
both COVID-19 ARDS and non-COVID-19 ARDS. In the con-
text of neutrophils, a terminally differentiated cell, this may 
hint to processes involved in the unravelling of DNA for NET 
formation rather than cell cycle control and serves as an 
interesting concept for further exploration.
A striking clinical divergence between COVID-19 and 
non-COVID-19 ARDS is the prominence of micro and macrov-
ascular thrombosis in COVID-19 ARDS. Here, we report pro-
teomic signatures indicative of platelet degranulation and clotting 
cascade activation. These observations together with evidence of 
neutrophil platelet binding, extend the previously reported 
contribution of neutrophils to the pathogenesis of immune 
clot formation through the release of NETs to one of TLR 
mediated neutrophil activation and the formation of neutrophil 
platelet aggregates. It is interesting to note that it is the neutrophils 
within the low density layer we observe by confocal microscopy 
to bind to platelets and to be associated with the upregulating 
the Mac-1 platelet binding complex in COVID-19 ARDS. 
Further work will be required to understand whether LDN also 
demonstrate a propensity for NETs formation, and whether these 
aggregates, previously reported in the lung tissue at post-mor-
tem, impair neutrophil transmigration and directly contribute to 
vascular damage and to the formation of microthrombi17–19. 
It will also be important to dissect whether the uplift in 
expression of proteins associated with fibrin clot formation 
in COVID-19 ARDS is consequent upon intrinsic neutrophil 
expression of these proteins, neutrophil processing of 
platelet proteins or reflective of adherent platelets contributing to 
the protein signatures of the circulating neutrophil populations.
The importance of neutrophil activation of type I IFN sig-
nalling pathways in COVID-19 ARDS also requires further 
consideration given the disconnect between tissue injury and 
viral detection47. The ability of neutrophils to cross-present exog-
enous antigens to CD8+ T cells has previously been reported 
and is highly relevant for T cell priming in vivo48. This may 
be particularly relevant in a disease where early CD4+ and 
Page 18 of 22
Wellcome Open Research 2021, 6:38 Last updated: 22 FEB 2021
Figure 8. Metabolic rewiring of COVID-19 ARDS neutrophils correspond to changes in neutrophil metabolism in response to 
type I interferon. (A) Glycolytic behaviour as determined by extracellular flux analysis during the glycolysis stress test in hypoxia (3% O2). HC NDN were cultured in hypoxia (1% O2) with IFNα/ IFNβ (IFN) or without (UT) for 3 h before sequential injections of resiquimod (RES), glucose (G), oligomycin A (OA) and 2-deoxyglucose (2DG) and extracellular acidification rate (ECAR) determined and used to calculate 
glycolysis and glycolytic capacity (Glyc. Cap.). Data are mean ± SD (n = 5, individual data points represent mean of at least two technical 
replicates from individual donors). *p < 0.05, **p < 0.01, determined by repeated measures one ANOVA and Tukey’s post hoc-testing. 
(B–D) Lactate (B), TCA intermediaries (C) and glutamate (D) abundance in neutrophils cultured in hypoxia for 4 hours with IFNα/ IFNβ 
(H-I/spotted bars) or without (H-U/open bars) relative to normoxic untreated control cells and determined by hydrophilic interaction liquid 
chromatography–mass spectrometry (p-HILIC LC-MS). Data are mean ± SD (n = 4, individual data points represent individual donors). 
*p < 0.05, **p < 0.01 determined by ratio paired t-test. (E) Glutamine and glutamate isotopomer abundance (Arbitrary Units, AU) as 
determined by p-HILIC LC-MS in neutrophils cultured as in (B–D) in the presence of 2 mM U-13C5 glutamine for 4 h. Individual data points 
represent individual donors, n = 4. Data are mean ± SD. *p<0.05, determined by paired t-test. (F–I) D-glucose (F), lactate (G), TCA intermediary 
(H) and glutamate (I) abundance in normal density neutrophils (NDN) isolated from healthy controls (HC/open bars, n= 5) and patients with 
non-COVID-19 ARDS (NA/spotted bars, n = 6) or COVID-19 ARDS (CA/diagonal striped bars, n = 9 with six patients receiving dexamethasone 
treatment indicated by open symbols) was determined by ion pair LC-MS (arbitrary units, AU). Data are mean ± SD (F, G and I) or median ± 
I.Q.R (H). HC, NA and CA were compared by student’s t-test (F, G and I) or Mann-Whitney (H) where *p < 0.05 and **p < 0.01.
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CD8+ T cell responses against SARS-CoV-2 are thought to be 
protective49,50, but late responses are associated with damaging 
inflammation50–53. Whilst activation of anti-viral responses 
including class I MHC antigen presentation would therefore appear 
beneficial with respect to viral control, if this is associated with 
a hyper-inflammatory neutrophil phenotype and delayed T cell 
activation, the net consequence could be persistent tissue injury. 
In this regard, we would predict that inappropriate degranulation 
of neutrophils in the circulation would be highly damaging and 
cause wide-spread inflammation within the microvasculature 
where neutrophils are known to be sequestered. Our evidence 
of expanded neutrophil numbers together with increased 
neutrophil activation and degranulation confirmed by the 
detection of plasma neutrophil granule proteins in patients 
with COVID-19 ARDS and TLR-agonist in vitro assays would 
support this concept of a hyper-inflammatory, damaging 
circulating innate response. These pro-thrombotic hyperinflam-
matory neutrophil protein signatures would appear to be retained 
in patients with COVID-19 ARDS receiving dexamethasone 
therapy. This is perhaps not surprising given the paucity of 
evidence for the impact of corticosteroids on neutrophilic 
inflammation, highlighting the need for additional therapeutic 
strategies.
Finally, the mechanism by which type I IFN regulates 
neutrophil behaviour remains to be fully elucidated. In pDC, 
TLR 9 mediated activation is dependent upon autocrine produc-
tion of type I IFNs and an increase in oxidative metabolism43. 
Neutrophils are unique in their reliance on non-oxidative 
metabolism for ATP production, even when oxygen is freely 
available. It is therefore of interest that in response to IFNα and 
IFNβ, neutrophils rewire their metabolic programme by reduc-
ing their glycolytic potential. Together with an increase in 
detectable levels of glutamate in neutrophils isolated from 
patients with COVID-19 ARDS, and existing evidence that 
neutrophils can undergo gluconeogenesis54, this raises the 
interesting possibility that ARDS neutrophils re-wire their 
metabolic processes to facilitate ongoing inflammatory responses 
which may be detrimental to the host. Future work will be 
required to better understand whether these metabolic changes 
potentiate anti-viral and pro-inflammatory innate immune 
responses following viral challenge. Of interest small molecules 
already exist for targeting glutamine utilisation and have been 
trialled in the cancer setting, raising the possibility of metabolic 
drug repurposing for the treatment of COVID-1955.
In summary, using mass spectrometry we describe patho-
physiological protein and metabolic neutrophil signatures 
that are common to ARDS and those distinct to COVID-19 
ARDS. We identify a type I IFN response in COVID-19 ARDS 
neutrophils which is associated with metabolic rewiring, neu-
trophil degranulation and the formation of neutrophil platelet 
aggregates in the blood which persist irrespective of dexametha-
sone treatment. A clear limitation of this study is the relatively 
small number of patients recruited. This is balanced against the 
detailed analysis we have been able to perform in these patient 
groups and the move towards functional dissection of neutrophil 
responses not previously captured in transcriptional data sets. 
Further understanding of the mechanisms which regulate aber-
rant neutrophil responses will likely be important in developing 
strategies to target the innate responses following infection with 
SARS-CoV-2 to enable an effective therapeutic arsenal for 
COVID-19 ARDS.
Data availability
PRIDE: Raw mass spectrometry data files and Spectronaut 
analysis files have been deposited to the ProteomeXchange30 
Consortium via the PRIDE31 partner repository, Accession number 
PXD023834: https://identifiers.org/pride.project:PXD023834.
Figshare: A type I IFN, prothrombotic hyperinflamma-
tory neutrophil signature is distinct for COVID-19 ARDS. 
https://doi.org/10.6084/m9.figshare.13637630.v233.
This project contains the following underlying data:
     •      Exp data_interferon_metabolites.csv (metabolite abundance 
data for each patient)
     •     Exp data_patient_metabolites.csv (metabolite abundance 
data for each patient)
     •     Exp data_interferon_seahorse_kinetic.csv (Seahorse kinetic 
data)
     •     Exp data_interferon_seahorse_parameters.csv (Seahorse 
parameter data)
     •     Figure 2D.csv - Figure 6O.csv (ELISA and flow 
cytometry data underlying corresponding figures)
     •      Flow_cytometry_fcs.zip (folder containing raw flow 
cytometry data in FCS format)
     •     Confocal.zip (folder containing original unedited 
microscopy images files in TIF format and flow cytometry 
data in FCS format underlying Figure 5C)
     •     Patient demographic.docx (patient demographic data)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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